The Canadian cannabis space got a positive double whammy this week in the form of quarterly results from two licensed producers.

Both Organigram Holdings (NASDAQ:OGI,TSX:OGI) and Aphria (NYSE:APHA,TSX:APHA) issued their latest quarterly reports on Tuesday (January 14), putting up impressive numbers following a taxing few quarters for cannabis equities.

The broader cannabis sector overall saw increases thanks in part to the release of these updates. The ETFMG Alternative Harvest ETF (ARCA:MJ) was up 3.2 percent on Tuesday, while the Horizons Marijuana Life Sciences Index (TSX:HMMJ) was up 3.6 percent that same day.

Organigram now “back on track,” analysts say

Organigram surged over 25 percent across the trading day on Tuesday and into market open on Wednesday (January 15) in Toronto after doubling its quarterly net revenue year-over-year.

The company’s net revenue for the first fiscal quarter of 2020 reached C$25.2 million, up 102 percent from the C$12.4 million reported in the year-ago period.

In a note sent out to investors, CIBC Capital Markets analysts John Zamparo and Krishna Ruthnum said the firm is “back on track” and the results are an encouraging sign in a difficult operating environment.

The pair noted that the company’s dependence on wholesale revenues, which made up a significant chunk of Organigram’s overall cash generation this past quarter, isn’t sustainable in the long term, but does speak to its ability to cultivate low-cost cannabis.

“Our only concerns out of the quarter are a capital projects to-do list that should see spending remain stubbornly high, and questionable timing of equity financing,” the analysts said.

Impressive returns from Cannabis 2.0 products are also mentioned in the note. During an earnings call on Tuesday, Organigram CEO Greg Engel said the company plans to add its line of cannabis-infused chocolates to its portfolio of ingestible offerings before the end of March after receiving licensing approval for chocolate production in December.

Ruthnum and Zamparo have listed the firm as an “outperformer” with a C$5 price target. Organigram’s share price sat at C$4.53 as of 3:23 p.m. EST on Thursday.

Analysts from Haywood Securities are also bullish on Organigram, noting that the company is set for a rerating in the larger cannabis sector.

Neal Gilmer, Ethan Spence and Colin George sent out a note to clients on Wednesday with raised estimates for Organigram’s fiscal 2020 year and a price target of C$6.50.

“Going forward we expect continued growth to be propelled by sales into the provinces for recreational adult-use will drive positive (earnings before interest, taxes, depreciation, and amortization) in fiscal 2020,” the trio said.

The Haywood analysts also said that thanks to the firm’s store of cash, sitting at C$34.1 million by quarter end, Organigram has enough funding to support its ongoing operations.

Aphria upgraded to “neutral” on solid market share gains

While it wasn’t as dramatic as Organigram’s boost, Aphria has also experienced an increase in its trading value on the open market. On Thursday its share price was up 4.8 percent since the firm released a report for its second 2020 fiscal quarter on Tuesday.

Net cannabis revenue for the Canadian producer hit C$33.7 million — C$29 million of which was generated by adult-use cannabis sales — representing a 9 percent increase quarter-over-quarter.

While the quarter’s total net revenue, C$120.6 million, is an increase of 457 percent year-over-year, it is a drop of 4 percent from Aphria’s previous quarter.

Aphria ended the quarter with a healthy store of C$497.7 million in cash.

The pair from CIBC upgraded Aphria to “neutral” and increased its price target to C$7 up from C$6.50.

Zamparo and Ruthnum indicated that Aphria’s ability to increase its market share in Ontario, now up to 13.8 percent, represents an encouraging move.

However, the company’s high spending, particularly at its operations in Colombia and Europe, with no return on capital in sight, is a point of concern for the duo, even though they said Aphria is largely in good shape at the moment.

“We believe current valuation leaves only modest upside, but Aphria should be able to survive regardless of the pace of evolution in Canada’s cannabis market,” said Zamparo and Ruthnum.

In its outlook for 2020, Aphria projects that its net revenue will be anywhere from C$575 million to C$625 million, slashing its old estimates of between C$650 million and C$700 million, which were previously noted in its report for 2020’s first fiscal quarter.

During an earnings call, CFO Carl Merton said the guidance reduction was due in part to the slow rollout of retail stores in Ontario.

The Haywood analysts said they continue to hold that Aphria is poised to become a leader in the cannabis space and currently trades at a discount compared to its contemporaries.

They did, however, drop their estimate to C$10.25 from C$11.75 based on the lowered guidance.

Don’t forget to follow us @INN_Cannabis for real-time news updates!

Securities Disclosure: I, Danielle Edwards, hold no direct investment interest in any company mentioned in this article.

 BioHarvest Sciences Inc. (CSE: BHSC) (the “Company” or “BioHarvest”) invites its shareholders and the general public to join a Live Video Conference (“Webinar”) on Thursday, January 21st, 2021 at 2:00 PM Eastern Standard Time (11:00 AM Pacific Standard Time). Ilan Sobel, CEO of BHSC, will host the event and discuss progress on Bioharvest’s Growth Plan, which will include highlights of the 2020 milestones achieved, key business capabilities built, and will provide an important overview of 2021 Priorities.

The presentation will be approximately 35 minutes, followed by a live question and answer session.

Keep reading... Show less

World-Class Extractions Inc. (CSE:PUMP)(FRA:WCF)(OTCQB:WCEXF) (the “Company” or “World-Class”), reports that it has sold its 50% interest in Cobra Ventures Inc. (“Cobra”), which sale included all funds previously advanced by World Class to Cobra, to the remaining shareholder of Cobra, for $2,500,000 in cash

An investment group led by Richard Goldstein retains 100% control of Cobra, and its senior secured debenture of Hydrx Farms Ltd. (“Hydrx”), acquired by Cobra in October 2020.

Keep reading... Show less

Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos Group” or the “Company”), an innovative global cannabinoid company, today announced that Kurt Schmidt, President and Chief Executive Officer, will speak at the 24th Annual CIBC Western Institutional Investor Conference on Friday, January 22, 2021 at 4:10 p.m. EST.

A recording will be available on the Investors section of the Company’s website at .

Keep reading... Show less
  • Disease control of root-rot Aphanomyces zoospores in laboratory tests.
  • Outstanding Efficacy: 100% control at economic application rates within 24 hours.
  • Aphanomyces is a soil-borne root-rot disease that destroys peas, lentils, and legume crops.

MustGrow Biologics Corp. (CSE: MGRO) (OTC: MGROF) (FSE: 0C0) (the “Company”, “MustGrow”) is pleased to announce successful laboratory test results of its patented mustard-derived biopesticide on Aphanomyces euteiches zoospores (“Aphanomyces”) via an independent third party facility: 100% control at economic application rates within 24 hours. MustGrow will now advance to larger scale greenhouse and field tests. Study results and applicability are patent-protected under MustGrow’s existing suite of issued patents.

MustGrow’s remarkably safe and effective organic biopesticide is plant-based – harnessing the mustard seed’s natural defense mechanism to control diseases, pests, and weeds with an organic food-grade biopesticide.

Keep reading... Show less

Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco” or “the Company”), one of the largest vertically integrated multistate cannabis operators in the United States, announced the hiring of CPG industry veteran Ty Gent as the Company’s new Chief Operating Officer (“COO”). As COO, Gent will be responsible for operational consistency and efficiency across markets and implementation of structural enhancements to facilitate scaling.

This press release features multimedia. View the full release here:

Keep reading... Show less